[go: up one dir, main page]

WO1995011659A2 - Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation - Google Patents

Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation Download PDF

Info

Publication number
WO1995011659A2
WO1995011659A2 PCT/UA1994/000025 UA9400025W WO9511659A2 WO 1995011659 A2 WO1995011659 A2 WO 1995011659A2 UA 9400025 W UA9400025 W UA 9400025W WO 9511659 A2 WO9511659 A2 WO 9511659A2
Authority
WO
WIPO (PCT)
Prior art keywords
выс
treatment
preparation
κleτοκ
indicators
Prior art date
Application number
PCT/UA1994/000025
Other languages
English (en)
Russian (ru)
Other versions
WO1995011659A3 (fr
Inventor
Andrei Semenovich Efimov
Alexandr Ivanovich Smikodub
Alla Vladimirovna Novits'kaya
Original Assignee
Tsentr Embrionalnych Tkanei 'emcell'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsentr Embrionalnych Tkanei 'emcell' filed Critical Tsentr Embrionalnych Tkanei 'emcell'
Priority to NL9420012A priority Critical patent/NL194693C/nl
Publication of WO1995011659A2 publication Critical patent/WO1995011659A2/fr
Publication of WO1995011659A3 publication Critical patent/WO1995011659A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes

Definitions

  • the vast majority of the invention is in the field of medicine, in particular in the form of cell therapy and can be used to treat a disease that causes 10 cases of diabetes.
  • the healthy transplantation is an attractive alternative for the loss of food and tissue, as it is immune to the cardiomyopathy
  • the cages have a large living potential. They are differentiated, differentiated, and are the source of a large number of biological active substances. ⁇
  • cell suspensions that are obtained from the fetal brain, liver, liver, spleen, thymus, and pancreas.
  • 35 cellular suspensions in the quality of medicines were related to the fetal liver and spleen. It is known that in the liver or spleen an embryo of a person in the ages of 5 to 16 weeks, there is a high content of absenteeism. ⁇ data on the developmental period of the carriage of the fetal liver and spleen only in
  • the mechanism of the development of insulin-dependent diabetes mellitus includes autoimmune Langgang outlets with cellular and circulating antibodies. Therefore, in the following treatment of insulin - dependent diabetes mellitus is used drugs, substances, tissue, directed to the prevention of autoimmune
  • a medication obtained from the thymus gland thymalin isolated from the thymus calf, and its use as an immune system for the treatment of diabetes, hepatitis B., , ⁇ .35, ⁇ ° 6, p. 7-9).
  • the main task of the invention was to create such a medication with an immune-mediated effect on the basis of a healthy outcome, in good health,
  • the posed problem is solved in that, in the medication of immunosuppressive activity on the basis
  • the 20 contained dimethyl sulfide in quantities of 3 to 10%.
  • the lower part of the unit is conditioned by the highest quality of the cells, and the upper part is based on the operation of the device.
  • the task posed is also solved in that way in the treatment of diabetes mellitus, which is included in the introduction
  • 35 cellular suspensions of the claimed composition can be very successful for the treatment of diabetes mellitus.
  • a suitable pharmaceutical preparation in a dose of 0.5 ml to 5 ml.
  • the medical device can be conveniently selected from a randomized bank of various types taking into account the inconvenience of
  • the product is declared to be ready for use 35 times, using the following procedure
  • the embryo is transferred to a stable vessel with the product of the anxiety and antibiotic / aminoglycides group /. Further work is carried out under stable conditions of the box. The embryos are transferred to the stylish cups of the Patent, filled with the emergency of Antibiotics, where there is a simple opening of the pit
  • Corresponding units are placed in homogenizers, cut into smaller fragments and grind to receive one mass.
  • the flasks wash off the wall and the vest
  • a dimethyl sulfide is used as a chemical compound ( ⁇ , chemically pure).
  • ⁇ chemically pure.
  • the suspension adds to the accumulator an equal amount of working space for the device by achieving an increase in the percentage of 5%.
  • the slurries are poured into plastic containers, depending on further goals with a volume of 0.5
  • the domestic refrigerators are placed in a chamber of a freezer operating on liquid nitrogen and freeze to - 196 ° C.
  • blowing indicators 35 embryonic fabrics in liquid nitrogen at a temperature of 196 ° ⁇ . After mounting the suspension, the following shall be determined: blowing indicators:
  • 10 cellular suspensions are used and stored in a can of bank, the following parameters: 1st - 5 90 90 * 10 6 ml ⁇ - 2 - - 20 rete 80 * 10 3 ml 3 1 3 - 0 5 up to 9 * 10 3 ml - 1 4th - out 1 up to 9 * 10 6 ml ⁇ - 15
  • the diagnostic diagnosis includes tests for syphilis, VHF, viral infection and diabetes, and Research is carried out on compatible bakteialnoy stability. 20 Detailed diagnostics include testing for availability
  • brackets containing at least 10 selectable methods for the reaction of the use of oligomerization using alternatives are provided.
  • Peripheral lymph nodes are not enlarged. Pulse - 98 beats / min., Rhythmic, increased voltage and voltage. The pressure of 190/120 mm. ⁇ . ct.
  • the heart is of good sounding, rhythmic, systematic noise on the air, accent II is on the sound. ⁇ Vesicular breathing is easily heard. The life is soft, moderately swollen, sensitive to palpation in the region of the other side of the coast.
  • the liver is ejected from - at the front of the external border of the arc on the second middle line by 2 cm.
  • the spleen is not enlarged.
  • the thumbs down are smashed.
  • Chair - 4 times a day, beautiful.
  • Daily diuresis up to 1 l.
  • the faces, the stoops, the genies are flowing.
  • Diabetic universal angiopathy nephropathy of III st., ⁇ PI 1 st.; Judicial form of treatment of retort; micropathy of the second invasion
  • Diabetic disease of the lower extremities Severe severity. Symptomatic Hypotension.
  • ED / SUT disinfectant therapy (enterosorbents, homeopathy, washing the intestines), diuretics, hypertensive, angiogenesis, angiotherapies
  • the plantation has been painfully reimbursed. After 8 - 10 hours, the syndrome was observed
  • Diabetes mellitus type 1
  • first diagnosed with severe form of illness in the event of compensation
  • the glycemia level was 15 mmol / l, glucose - 41.6 g / l, and aceturia - / + + + /.
  • Appointed treatment insulinotherapy - 60 carteD per day, vitamin therapy, potassium preparations.
  • the patient was in a compensated building with a stable, stable, low, daily, effective insulin supply.
  • the diagnosis was established: Diabetes mellitus, type 1, first diagnosed, severe form, in the case of compensation, diabetic catacidosis. During the reduction, the glycemia level was 20.0 mmol / l, glucose - 52.4 g / l, acetonuria - 5 / + + + /.
  • Appointed treatment insulinotherapy - 64 days of treatment, vitamin therapy, potassium preparations, hemedes 200.0 after a day ⁇ ° 6.
  • the azathiopyrine was prescribed in a daily dose of 2 mg per 1 kg. body mass in two ⁇ emia starting from 25 mg. in fact, steadily increasing the dose by daily control of the 0-circle. In order to improve the indicated therapeutic dose, the treatment was treated with a weekly treatment of patients with drugs, erythrocytes and drugs.
  • Treatment with an azithioprine was continued for 48 days after the transplantation of hematopoietic cells of the human embryo liver.
  • the disease commission lasts more than 9 months.
  • Diagnosis Insulin-dependent diabetes mellitus, severe form, labile course, state of compensation.
  • the disease was detected in February 1993, when a child was delivered to the intensive care unit in a pediatric unit.
  • Diagnosis Insulin-dependent diabetes mellitus, severe 0 form, labile course, state of compensation, diabetic universal angiopathy of the second stage, diabetic disease. Russian cholecystitis, phase of remission.
  • Basic 5 is a disease that is generally labile: a frequent change in the status of catheter or hypoglycemia and minor changes in the disease A large, state-of-the-art department for the treatment of the transplantation of a human patient’s breast cell.
  • ZETS 3038 - Yu ⁇ embryo ingestion - 6 weeks, quantitatively available live cells 8.5 * 10 6 / ml, volume of introduced tissue - 2.5 ml, ⁇ ⁇ - 23 * 10 3 / ml, ⁇ bl. - 2.4 * 10 3 / ml, ⁇ 3 4 - 3.8 * 10 6 / ml_
  • the method of administration is internal.
  • the erythrocytes containing the fetal hemoglobin are divided into 8–10%.
  • Diagnosis Diabetes mellitus, type 1, severe form of companion, universal diabetic angiopathy: small-angiopathic vessels of the lower end, III.
  • the patient was treated as an outpatient without a result. After the last bath, the drain turned off, the grains intensified, the disease manifested itself in severe skin disease, and the temperature increased to 38 ° ⁇ . Immediately after the phlegmon has been opened, the appliance is manufactured.
  • Antibiotics, antipyretic drugs, insulin therapies were assigned - 38 limestoneD per day.
  • the state of health did not change: body temperature rises in the evening at 38.6 ° C, general weakness, dull discharge from the incision and the urinary tract were reduced.
  • After a third day a lower, lower-left pneumonia was heard from a large patient. Bacteriological crops of cultivar, urine, feces are produced.
  • ⁇ izvedena ans ⁇ lan ⁇ atsiya na ⁇ ivny ⁇ gem ⁇ e ⁇ iches ⁇ i ⁇ ⁇ le ⁇ emb ⁇ i ⁇ naln ⁇ y ⁇ echeni chel ⁇ ve ⁇ a / ⁇ b ⁇ azets 3038S - 57 ⁇ /: v ⁇ z ⁇ as ⁇ emb ⁇ i ⁇ na - 8 weeks ⁇ liches ⁇ v ⁇ yad ⁇ s ⁇ de ⁇ zhaschi ⁇ ⁇ le ⁇ - 37.5 * 10 / ml, ⁇ bem vvedenn ⁇ y ⁇ ani - 2.5 ml, ⁇ G ⁇ - 42 * 10 3 / ml, ⁇ bl. - 1.3 * 10 3 / ml, ⁇ 3 4 - 1.4 * 10 6 / ml, with the method of administration - internal.
  • the diagnosis was established: Diabetes mellitus, type 1, first diagnosed, severe form, condition of compensation, 25 diabetic catacidosis. With the onset of glycemia - 20, 2 mmol / l, glucose - 51.2 g / l, acetonuria - / + + + + /. Appointed treatment: insulinotherapy - 62 days of treatment, vitamin therapy, potassium preparations.
  • the cultivated culture made up 50%.
  • the dynamics of changes in the quantity of red blood cells containing a fetal hemisphere indicates a transient remnant of cells.
  • the disease commission lasts more than twelve months.
  • the proposed medication and method of treating diabetes with the aim of using the drug have the following effects:
  • diabetes mellitus as infectious, micro- and macropathy, neuropathy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne la médecine et en particulier la thérapie cellulaire. L'invention concerne une préparation pharmaceutique caractérisée par la composition spécifique ainsi que des indicateurs quantitatifs d'une suspension cellulaire obtenue à partir de tissus hématopoïétiques natifs ou conservés de façon cryogénique tirés du foie et/ou de la rate d'un embryon humain. De plus, l'invention concerne un procédé de traitement du diabète sucré consistant en l'introduction de ladite préparation pharmaceutique, laquelle est sélectionnée en fonction des indicateurs individuels du patient à partir d'une banque de tissus créée spécialement, contenant une variété d'échantillons, le même échantillon étant utilisé pour une application ultérieure.
PCT/UA1994/000025 1993-10-18 1994-10-17 Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation WO1995011659A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL9420012A NL194693C (nl) 1993-10-18 1994-10-17 Werkwijze voor het bereiden van medicinale preparaten voor het behandelen van diabetes.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
UA94020324A UA27048C2 (uk) 1993-10-18 1993-10-18 Лікарський препарат імуhокоригуючої дії hа осhові клітиhhої суспеhзії, спосіб лікуваhhя цукрового діабету з використаhhям цього препарату
UA94020324 1993-10-18

Publications (2)

Publication Number Publication Date
WO1995011659A2 true WO1995011659A2 (fr) 1995-05-04
WO1995011659A3 WO1995011659A3 (fr) 1995-06-01

Family

ID=21688946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/UA1994/000025 WO1995011659A2 (fr) 1993-10-18 1994-10-17 Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation

Country Status (5)

Country Link
CA (1) CA2152078A1 (fr)
NL (1) NL194693C (fr)
RU (1) RU2126260C1 (fr)
UA (1) UA27048C2 (fr)
WO (1) WO1995011659A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2226104C2 (ru) * 1998-12-16 2004-03-27 Центр эмбриональных тканей "ЭМСЕЛЛ" Способ лечения людей эмбриональными клеточными суспензиями
UA64826C2 (uk) * 1998-12-16 2004-03-15 Центр Ембріональних Тканин "Емселл" Спосіб лікування людей ембріональними клітинними суспензіями
RU2160112C1 (ru) * 2000-04-10 2000-12-10 Сухих Геннадий Тихонович Способ приготовления клеточного трансплантата из фетальных тканей
RU2219894C2 (ru) * 2001-01-03 2003-12-27 Лобова Любовь Иннокентьевна Способ лечения сахарного диабета у детей и подростков
RU2191388C1 (ru) * 2001-12-18 2002-10-20 Закрытое акционерное общество "РЕМЕТЭКС" Культура нервных стволовых клеток, биотрансплантат для аллопересадки и способ его приготовления
RU2261049C2 (ru) * 2003-03-18 2005-09-27 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" Способ лечения больных с диабетической гангреной нижних конечностей
RU2280462C2 (ru) * 2004-04-09 2006-07-27 Александр Сергеевич Тепляшин Способ выделения мезенхимальных стволовых клеток
RU2265443C1 (ru) * 2004-05-14 2005-12-10 ЗАО "РеМеТэкс" Биотрансплантат и способ лечения сахарного диабета i и ii типа (варианты)
RU2301069C2 (ru) * 2004-06-10 2007-06-20 Муниципальное учреждение здравоохранения "Городская клиническая больница №3" Способ лечения осложненных форм варикозной и посттромбофлебитической болезней
RU2250773C1 (ru) * 2004-07-16 2005-04-27 Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ (ЦНИРРИ) Способ лечения аллергических заболеваний
RU2290808C2 (ru) * 2004-12-06 2007-01-10 Институт физиологии Коми научного центра Уральского отделения Российской Академии Наук Криопротекторный раствор для замораживания лейкоцитов при низкой температуре
RU2007112288A (ru) * 2007-04-03 2008-10-10 Александр Сергеевич Ботин (RU) Композиция для стимулирования роста и регенерации клеток, а также способ ее получения
RU2441284C2 (ru) * 2008-03-25 2012-01-27 Оксана Валентиновна Вежан Способ повышения физической выносливости в эксперименте

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592637A (en) * 1978-03-22 1981-07-08 Parmer L P Lipid extract for inhibiting platelet function in blood
US4254103A (en) * 1979-06-08 1981-03-03 Institul de Cercetari Chimicofarmaceutice Hepatoprotector Factor (HF) and method of treatment
HU182087B (en) * 1980-01-15 1983-12-28 Mta Kiserleti Orvostudomanyi K Process for preparing an active substance for the selective inhibition of the multiplication of normal cells and of cells in myeloide leukemia
SU1158201A1 (ru) * 1983-06-03 1985-05-30 Ленинградское Ордена Ленина,Ордена Трудового Красного Знамени Производственное Объединение Мясной Промышленности Им.С.М.Кирова Способ получени стимул тора из селезенки млекопитающих
US5055296A (en) * 1988-08-04 1991-10-08 Wagle Sudhakar S Method of treating chronic fatigue syndrome
IT1244879B (it) * 1990-12-11 1994-09-12 Alberto Bartorelli Estratti da tessuti animali, utili in terapia e in diagnostica.

Also Published As

Publication number Publication date
NL9420012A (nl) 1995-12-01
NL194693C (nl) 2002-12-03
NL194693B (nl) 2002-08-01
WO1995011659A3 (fr) 1995-06-01
CA2152078A1 (fr) 1995-05-27
RU2126260C1 (ru) 1999-02-20
UA27048C2 (uk) 2000-02-28

Similar Documents

Publication Publication Date Title
Hamstra et al. Intravenous iron dextran in clinical medicine
Elkinton et al. Effects of pituitary adrenocorticotropic hormone (ACTH) therapy
WO1995011659A2 (fr) Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation
THORN et al. Pheochromocytoma of the adrenal associated with persistent hypertension; case report
Aubert et al. The universal donor with high titre iso-agglutinins
Lerman et al. The pituitary type of myxedema: Further observations
JP2008534529A (ja) 自家造血幹細胞の調製物、その製造方法、低温保存方法、および中枢神経系の外傷性疾患の治療のための使用
WO1995016455A1 (fr) Preparation pharmaceutique a proprietes d'immunosubstitution, basee sur une suspension cellulaire, et procede d'utilisation de la dite preparation dans le traitement du syndrome d'immunodeficience acquise (infection vih)
DISTENFELD et al. The treatment of acute thrombotic thrombocytopenic purpura with corticosteroids and splenectomy: Report of three cases
Best The internal secretion of the pancreas
Banting An address on diabetes and insulin: being the Nobel lecture delivered at Stockholm on September 15th, 1925
WO1997048405A1 (fr) Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes
Isaacs et al. Tapeworm Anemia: Therapeutic Observations
RU2063760C1 (ru) Способ лечения печеночной недостаточности при хронических заболеваниях печени
Clarke et al. Host immune status in uremia. V. Effect of uremia on resistance to bacterial infection
Mihic et al. Effect of trimethoprim-sulfamethoxazole on blood insulin and glucose concentrations of diabetics
WO1991000098A1 (fr) Preparation anti-inflammatoire et son procede d'obtention
EP1437140A1 (fr) Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation
Gray Cortisone and ACTH
Kleeman et al. Effect of various diuretic agents on maximal sustained water diuresis
HAYNBS JR The management of burns in children
Kreidberg et al. Clinical evaluation of corticotropin therapy in children
Prowse Fatality Due to the Use of Gold
Soriano Sugar, Spice, Too Much or Little of Everything is Not Nice: An Immunological Discussion on the Global Diabetes Epidemic
GLASS et al. UNUSUALLY HIGH INSULIN REQUIREMENTS IN DIABETES MELLITUS: REPORT OF A CASE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA ES NL RU US

AK Designated states

Kind code of ref document: A3

Designated state(s): CA ES NL RU US

ENP Entry into the national phase

Ref document number: 9550021

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 009550021

Country of ref document: ES

Ref document number: P009550021

Country of ref document: ES

WWE Wipo information: entry into national phase

Ref document number: 2152078

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1995 481478

Country of ref document: US

Date of ref document: 19950915

Kind code of ref document: A

WWR Wipo information: refused in national office

Ref document number: 9550021

Country of ref document: ES

Kind code of ref document: A